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protein (L-FABP) were measured during and after surgery 
in both groups. Plasma renin activity, Ang II, aldosterone 
and serum creatinine were also measured.
Results Urinary angiotensinogen levels in the hANP group 
were significantly lower than in the non-hANP group after 
cardiopulmonary bypass surgery, at the end of surgery and 
3 h after surgery. At 3 h after surgery, urinary NGAL lev-
els in the hANP and non-hANP groups were 371.1 ± 413.6 
and 761.4 ± 437.8 μg/gCr, respectively (p < 0.01). Urinary 
L-FABP levels at the end of surgery in the hANP and non-
hANP groups were 238.8 ± 107.4 and 573.9 ± 370.1 μg/
gCr, respectively (p < 0.01). Moreover, hANP seemed to 
significantly reduce the incidence of postoperative AKI.
Conclusions hANP demonstrated renal protective effects 
during cardiac surgery, and could possibly reduce the inci-
dence of AKI after ischemia–reperfusion surgery. Moreo-
ver, this protective effect of hANP is likely induced by 
inhibition of the intrarenal RAAS.
Keywords Acute kidney injury · Cardiac surgery · Human 
atrial natriuretic peptide · Renin–angiotensin system
Introduction
Acute kidney injury (AKI) is a critical complication that can 
follow cardiac surgery. Previous studies reported that the 
incidence of cardiac surgery-associated AKI varies widely 
from 7 to 40%, depending on the definition [1]. Moreover, 
the high mortality of such patients has been recognized 
[2–4]. Cardiopulmonary bypass (CPB)-related injury to the 
kidneys involves numerous factors, such as hypoxia, vas-
cular endothelial injury, inflammatory reactions, activation 
of reactive oxygen species (ROS) and the renin–angioten-
sin–aldosterone system (RAAS). It has also been reported 
Abstract 
Purpose Acute kidney injury (AKI) is one of the critical 
complications after cardiac surgery. In the kidney, angio-
tensin II (Ang II) is formed by independent mechanisms, 
and activity of the intrarenal renin–angiotensin–aldosterone 
(RAAS) system contributes to the progression of kidney 
damage. Although atrial natriuretic peptide (ANP) exerts 
protective effects against renal injury by inhibiting the 
RAAS, the mechanisms of this effect have not been com-
pletely clarified. We investigated how human ANP (hANP) 
could prevent renal damage induced by cardiopulmonary 
bypass.
Methods Forty-eight patients undergoing cardiac surgery 
were divided into two groups, with and without hANP 
infusion. Urinary angiotensinogen, neutrophil gelatinase-
associated lipocalin (NGAL) and L-type fatty acid-binding 
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that the incidence of AKI after CPB surgery correlates with 
a high activity of renin [5]. Atrial natriuretic peptide (ANP), 
a hormone secreted primarily by atrial cardiomyocytes, is 
a potent natriuretic, diuretic and vasodilatory peptide that 
contributes to decreasing blood pressure [6]. Previous stud-
ies have found that human ANP (hANP) preserves renal 
function in patients undergoing coronary artery bypass sur-
gery [7, 8] and abdominal aortic aneurysm repair [9]. One 
study showed that continuous infusion of hANP during car-
diac surgery with CPB maintained postoperative renal func-
tion by preventing the activity of the RAAS [7]. Recently, 
expressions of local RAAS in specific tissues have been rec-
ognized, and, in the kidney, intrarenal angiotensin II (Ang 
II) has been found to be formed by independent mecha-
nisms [10]. In addition, use of urinary angiotensinogen as 
an index of the activity of the intrarenal RAAS has been 
assessed [11], and a previous study reported that elevated 
urinary angiotensinogen was associated with the develop-
ment of AKI after cardiac surgery [12].
Based on AKI diagnostic criteria, AKI is defined as an 
increase in serum creatinine (Cr) of ≥0.3 mg/dl or a rela-
tive increase of ≥1.5-fold from baseline [13, 14]. Further, 
even small serum Cr changes were reported to be signifi-
cantly associated with mortality in a cohort study of car-
diac surgery [15]. However, because there is a time lag 
in the increase of serum Cr following the occurrence of 
AKI, serum Cr is not an efficient early biomarker for the 
detection of AKI [16]. Therefore, in the present study, we 
examined two early urinary biomarkers as indices of AKI: 
neutrophil gelatinase-associated lipocalin (NGAL) and 
L-type fatty acid-binding protein (L-FABP). Both NGAL 
and L-FABP have been recognized as being effective in 
the detection of kidney injury, although the mechanisms of 
increasing urinary excretion of these two markers are quite 
different [17–20].
Previous research reported that the activity of the intra-
renal RAAS directly affects the progression of renal dis-
ease [10]. In addition, we previously showed in an animal 
experiment that ANP can prevent the activity of the intra-
renal RAAS [21]. Therefore, we hypothesized that ANP 
exerted renoprotective effects by inhibiting the activity 
of the intrarenal RAAS, not but the systemic RAAS. The 
primary endpoint of this study was to investigate whether 
hANP can prevent the occurrence of AKI during cardiac 
surgery, and the mechanisms of the renoprotective effects 
of hANP, with emphasis on the intrarenal RAAS, using 
NGAL and L-FABP as the biomarkers of AKI.
Materials and methods
The protocol of this study was approved by the Eth-
ics Committee of Kagoshima University Hospital and 
registered with the UMIN Clinical Trials Registry (UMIN 
000012312) on November 18, 2013. This clinical trial was 
registered before patient enrollment, and was conducted in 
accordance with the principles of the Declaration of Hel-
sinki. Prior written informed consent was obtained from 
each patient.
Study design and subjects
Forty-eight patients undergoing cardiac surgery with CPB 
except aortic grafting surgery were enrolled. Exclusion 
criteria were emergency operation, over 80 years of age, 
obese patients (BMI > 30 kg/m2), low left ventricular func-
tion (ejection fraction <40%) and preoperative renal dys-
function (serum Cr level >1.3 mg/dl). After exclusion, all 
patients were randomly divided into two groups using a 
computer-based stratified randomization method accord-
ing to patient’s age, sex and body mass index; one group 
received an infusion of hANP (carperitide; Daiichi-Sankyo 
Pharmaceutical Inc., Tokyo, Japan) and the other group was 
given an infusion of a nutrient-free saline solution in the 
same manner. We determined the sample size by analyzing 
the incidence of AKI in our institute based on Kidney Dis-
ease: Improving Global Outcomes (KDIGO) criteria.
Anesthesia and study protocol
Patients were prepared according to standard preoperative 
procedures after overnight fasting. Morphine hydrochlo-
ride (0.2 mg/kg, intramuscularly) was given 30 min before 
the induction of anesthesia. An intravenous catheter was 
inserted into a forearm vein, and a cannula was inserted 
into the radial artery under local anesthesia. Anesthesia 
then was induced by injecting 0.08 mg/kg midazolam, 
5 μg/kg fentanyl and 0.6 mg/kg rocuronium bromide intra-
venously. Propofol infusion was adjusted to the rate of 
4–10 mg/kg/h to maintain bispectral index (BIS; Aspect 
Medical Systems, Norwood, MA, USA) values within the 
range of 40–60. The remifentanil infusion was adjusted to 
the range of 0.1–0.5 μg/kg/min depending on surgical inva-
siveness. After induction of anesthesia, the lungs were ven-
tilated to normocapnia and red blood cells were transfused 
to maintain a hematocrit of 25% or more. Infusion of hANP 
at the rate of 0.025 μg/kg/min or an equivalent volume of a 
nutrient-free saline solution as placebo was performed via 
a central venous catheter inserted into the internal jugu-
lar vein, from the start of surgery till 12 h postoperatively. 
CPB was performed with non-pulsatile low-temperature 
perfusion (target rectal temperature: 34 °C). After surgery, 
all patients were transferred to the intensive care unit (ICU) 
and remained sedated for 3 h after surgery. Sedation was 
then discontinued and the trachea was extubated after con-
firming hemodynamic stability.
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Measurements
Plasma renin activity, Ang II and aldosterone were meas-
ured at five points [before surgery (base line), before and 
after CPB, at end of surgery, and 3 h after surgery]. At the 
same time points, urinary angiotensinogen was measured 
using specific ELISA kits (IBL, Gunma, Japan). Urinary 
NGAL and L-FABP levels were also determined using 
specific ELISA kits (Bioporto Diagnostics, Hellerup, Den-
mark, and CMIC Co. Ltd, Tokyo, Japan, respectively). Uri-
nary angiotensinogen, NGAL and L-FABP were adjusted 
for urinary creatinine concentrations. Moreover, serum Cr 
was measured preoperatively and on postoperative days 1, 
2 and 3.
Statistical analysis
Data are expressed as mean ± standard deviation (SD). 
Patient background and outcome variables between the two 
groups were compared using χ2 tests or unpaired Student’s 
t tests. Other data were analyzed with repeated measures 
ANOVA using GraphPad Prism software (version 5). We 
considered p < 0.05 to be statistically significant.
Results
Patient’s background
Patient characteristics in the two groups are shown in 
Table 1. There were no significant differences between 
the two groups. Since hypotension and hypovolemia often 
occur during cardiac surgery for many reasons, determina-
tion of whether hypotension, hypovolemia and electrolyte 
abnormalities are directly caused by hANP might be dif-
ficult. Therefore, we additionally analyzed the data on 
intraoperative urine output, red blood cell transfusion and 
fluid balance. We observed that there was no difference in 
the incidence of complications related to hANP, such as 
hypotension, hypovolemia and electrolyte abnormalities 
due to excessive urination, between the hANP and non-
hANP groups. If patients developed hypotension, phenyle-
phrine was mainly administered and volume loading was 
performed. The management of blood pressure was done 
according to the usual method at our institute, based on the 
decision of each anesthesiologist. However, no case of seri-
ous hypotension occurred because the dose of hANP was 
low. There was also no rebound phenomenon after discon-
tinuation of hANP administration in the current study.
Activities of systemic and intrarenal renin–angiotensin–
aldosterone systems
Urinary angiotensinogen increased immediately after 
CPB compared to baseline in both groups, although uri-
nary angiotensinogen levels were significantly lower 
in the hANP group than in the non-hANP group after 
CPB (hANP group 3.3 ± 1.4 mg/gCr versus non-hANP 
group 6.8 ± 3.6 mg/gCr; p = 0.04), at the end of sur-
gery (hANP group 5.8 ± 3.1 mg/gCr versus non-hANP 
group 10.2 ± 5.1 mg/gCr; p = 0.03) and 3 h after surgery 
(hANP group 5.6 ± 3.9 mg/gCr versus non-hANP group 
Table 1  Patient demographics
There were no significant differences between the two groups
ARB angiotensin receptor blocker, ACC aortic cross-clamp, CPB cardiopulmonary bypass, RBC red blood 
cell
hANP group (n = 24) Non-hANP group (n = 24)
Age (years) 64.7 ± 10.3 65.7 ± 10.9
Sex (male/female) 13/11 15/9
Body weight (kg) 54.2 ± 12.8 57.6 ± 10.9
Preoperative medication
 ARB 13 16
 β-Blocker 9 6
Diagnosis
 Coronary artery disease 9 7
 Valvular disease 15 17
Operating time (min) 364.7 ± 60.3 374.1 ± 65.1
ACC time (min) 102.2 ± 47.6 110.8 ± 50.1
CPB time (min) 154.7 ± 52.6 161.8 ± 49.1
Intraoperative urine output (ml) 935 ± 125.7 847 ± 91.6
Intraoperative RBC transfusion (ml) 1220 ± 187.3 1176 ± 171.8
Intraoperative fluid balance (ml) 2225 ± 425.3 1805 ± 189.1
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9.8 ± 6.6 mg/gCr; p = 0.04) (Fig. 1). Although renin activ-
ity, Ang II and aldosterone levels also started to increase 
after CPB compared to baseline in both groups, renin and 
Ang II levels did not differ significantly between the two 
groups (Fig. 2a, b). Aldosterone in the hANP group was 
significantly lower than in the non-hANP group only 3 h 
after surgery (Fig. 2c).
AKI biomarkers
Urinary NGAL and L-FABP levels in the non-hANP 
group reached a peak 3 h after surgery and at the end of 
surgery, respectively, with significant differences between 
the two groups in urinary NGAL and L-FABP levels at 
these time points. At 3 h after surgery, peak urinary NGAL 
levels in the hANP group and in the non-hANP group 
were 371.1 ± 413.6 and 761.4 ± 413.6 μg/gCr, respec-
tively (p < 0.01) (Fig. 3). On the other hand, peak urinary 
L-FABP levels at the end of surgery in the hANP and non-
hANP groups were 238.8 ± 107.4 and 573.9 ± 370.1 μg/
gCr, respectively (p < 0.01) (Fig. 4).
Serum creatinine and the incidence of postoperative 
AKI
Serum Cr did not differ significantly between the two 
groups on postoperative days 1, 2 and 3 (Table 2). How-
ever, there were 9 patients in the non-hANP group and 2 
patients in the hANP group who developed postoperative 
AKI, which was diagnosed by an increase in serum Cr of 
0.3 mg/dl or higher, based on KDIGO criteria [14]. Hence, 
the incidence of postoperative AKI was significantly lower 
in the hANP group (p = 0.04).
Discussion
The present study demonstrated that low-dose hANP dur-
ing CPB surgery could prevent an increase in NGAL and 
L-FABP, which are early biomarkers of AKI, and could 
reduce the incidence of postoperative AKI. Reportedly, 
low-dose hANP infusion protects renal function after car-
diac surgery via inhibition of systemic RAA activity [7]. 
However, in the present study, hANP could not completely 
prevent the increase in serum renin activity and Ang II and 
Fig. 1  Changes in urinary angiotensinogen from baseline (before 
surgery) to 3 h after surgery. Urinary angiotensinogen levels were sig-
nificantly lower in the hANP group compared to the non-hANP group 
at the time points of after CPB, at end of surgery, and 3 h after sur-
gery. uAng urinary angiotensinogen, CPB cardiopulmonary bypass
Fig. 2  Changes in renin activity (a), angiotensin II (b) and aldoster-
one (c) from baseline (before surgery) to 3 h after surgery. There were 
no significant differences in renin activities and angiotensin II levels 
between the hANP group and the non-hANP group. Aldosterone lev-
els were lower in the hANP group than in the non-hANP group at 3 h 
after surgery. CPB cardiopulmonary bypass
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aldosterone levels as compared to the control group, all 
these hormones being activated after CPB in both groups. 
Recently, the role of the local RAAS in several tissues, 
such as the kidney, heart, vasculature, adrenal gland, liver, 
spleen and skeletal muscles, has been emphasized [22]. In 
the kidney, all components of the renal RAAS are produced 
independently of the systemic RAAS, and contribute to 
the progression of both acute and chronic kidney diseases 
[10]. Intrarenal Ang II can be produced independently 
from circulating Ang II, its concentrations reportedly being 
far higher than plasma Ang II levels in AKI, and directly 
related to the progression of AKI [16]. Moreover, urinary 
angiotensinogen has been identified as an index of the 
activity of the renal RAAS [11]. Previous animal experi-
ments demonstrated that hANP attenuated renal injury that 
was induced by ischemia/reperfusion. The mechanism was 
attributed to inhibition of Ang II production and intrarenal 
RAAS activation, which, in turn, prevented the production 
of urinary angiotensinogen [21]. The present study showed 
that hANP could significantly prevent the increase in uri-
nary angiotensinogen levels after CPB, as compared to the 
control group, much earlier than prevention of the increase 
in both L-FABP and NGAL. On the other hand, hANP 
could not significantly prevent upregulation of the systemic 
RAAS, as indicated by plasma renin, Ang II and aldoster-
one levels, after CPB. Therefore, prevention of the activ-
ity of the renal RAAS, but not systemic RAAS, via hANP 
might inhibit the progress of renal damage after CPB. In a 
previous study, activation of the systemic RAAS occurred 
several hours or days later, by which time the biomark-
ers of AKI had already been upregulated [1]. Increasing 
activation of the intrarenal RAAS might follow the pat-
tern of systemic renin activity and Ang II and aldosterone 
concentrations.
The most frequent adverse event associated with hANP 
infusion is probably hypotension. The optimal dose of 
hANP for preventing postoperative AKI has not yet been 
established. We selected low infusion rates of 0.025 μg/
kg/min as the dose of hANP in the present study, almost 
half that used in previous clinical research, which did not 
result in excessive reductions in blood pressure [7, 8, 23]. 
Further, since no other noteworthy complications related to 
hANP infusion were observed, we believe that the dose of 
0.025 μg/kg/min of hANP would be safe and efficacious in 
clinical settings.
Serum Cr has long been used in the diagnosis of kidney 
disease. However, an increase in serum Cr only indicates 
renal clearance failure. It has been pointed out that creati-
nine kinetics are insufficient as an index of acute kidney 
injury. In the present study, serum Cr did not differ between 
the two groups on postoperative days 1, 2 and 3, despite the 
Fig. 3  Changes in urinary NGAL from baseline (before surgery) 
to 3 h after surgery. Urinary NGAL levels were lower in the hANP 
group than in the non-hANP group at 3 h after surgery. uNGAL uri-
nary neutrophil gelatinase-associated lipocalin, CPB cardiopulmo-
nary bypass
Fig. 4  Changes in urinary L-FABP from baseline (before surgery) 
to 3 h after surgery. Urinary L-FABP levels were lower in the hANP 
group than in the non-hANP group at the end of surgery. uL-FABP 
urinary L-type fatty acid-binding protein, CPB cardiopulmonary 
bypass
Table 2  Pre- and postoperative serum Cr and incidence of AKI
sCr serum creatinine
hANP group (n = 24) Non-hANP group (n = 24) p value
Preoperative sCr (mg/dl) 0.84 ± 0.21 0.86 ± 0.22 0.770
Postoperative day 1  sCr (mg/dl) 0.95 ± 0.42 0.99 ± 0.35 0.719
Postoperative day 2  sCr (mg/dl) 0.98 ± 0.25 1.07 ± 0.34 0.336
Postoperative day 3  sCr (mg/dl) 0.94 ± 0.30 1.02 ± 0.38 0.483
Incidence of AKI (based on KDIGO criteria) 2 9 0.036
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reduced incidence of postoperative AKI with hANP. Hence, 
we could not demonstrate renoprotective effects of hANP 
based on an increase in serum Cr, which is contrary to what 
has been shown in previous randomized controlled stud-
ies [7, 8]. Besides, serum Cr does not increase until at least 
24–48 h after the development of AKI. Recently, several 
research groups reported that small increments in serum Cr 
after cardiac surgery, which was not adopted as a diagnos-
tic criterion for AKI, was significantly associated with the 
progression of postoperative AKI and mortality [24, 25]. 
It is possible that hemodilution and hydration may lead 
to falsely low serum Cr measurements, which in turn can 
confound the diagnosis of AKI after cardiac surgery. This 
low accuracy of serum Cr measurements, in addition to the 
delay in the increase in serum Cr after cardiac surgery, is 
another drawback of using serum Cr as a marker of AKI. 
Since serum Cr is not a completely accurate marker in the 
early diagnosis of AKI, several early and specific biomark-
ers of AKI are strongly needed.
In the present study, we assessed two typical urinary 
biomarkers, NGAL and L-FABP, for their utility in the 
diagnosis of AKI. NGAL is a 25-kDa protein belonging to 
the lipocalin superfamily, which is secreted by neutrophils 
[26]. Urinary NGAL has been recognized as an early bio-
marker of AKI after cardiac surgery [17, 18]. On the other 
hand, L-FABP is a 14-kDa fatty acid-binding protein, and 
is a biomarker that is secreted in urine as a result of reactive 
oxygen stress. The usefulness of L-FABP as a biomarker 
in the early detection of AKI after cardiac surgery has also 
been reported [19, 20]. There is a difference between the 
mechanism of increase in urinary NGAL and L-FABP after 
CPB. Oxidative stress via renal tissue hypoxia upregulates 
L-FABP expression and increases the secretion of L-FABP 
into urine from damaged proximal tubules [27]. In contrast, 
inflammation induced by various stresses increases serum 
NGAL, while impaired renal absorption increases urinary 
NGAL secretion [28]. Therefore, the increase in urinary 
NGAL levels takes longer than urinary L-FABP levels 
[27]. In the present study, although both urinary NGAL and 
L-FABP concentrations increased immediately after CPB 
in both the non-hANP and hANP groups, hANP prevented 
the increase in urinary L-FABP at the end of surgery and 
NGAL 3 h after surgery. Moreover, hANP could signifi-
cantly prevent the increase in urinary angiotensinogen lev-
els compared to that in the non-hANP group immediately 
after CPB, well before the increase in both urinary NGAL 
and L-FABP. Ischemia–reperfusion injury induced by CPB 
is accompanied by augmentation of the intrarenal RAAS, 
and the activated intrarenal Ang II promotes renal tissue 
inflammation, resulting in an increase in urinary NGAL 
[28]. Ang II also inhibits oxygen delivery and increases 
oxygen consumption, which could induce the production 
of ROS [29], which in turn increases the expression and 
secretion of L-FABP into urine. This suggests that hANP 
exerts renoprotective effects against inflammation and 
ROS, which are activated by CPB.
The present study shows that hANP prevents demon-
strable activation of the intrarenal RAAS, but not sys-
temic RAAS, which has protective effects against kidney 
injury. Previous studies measured serum Cr and Cr clear-
ance, which increased 24 h postoperatively and beyond, to 
evaluate the renoprotective effects of hANP [7, 8, 23]. On 
the other hand, we demonstrated the possible use of earlier 
biomarkers, NGAL and L-FABP, in the diagnosis of acute 
renal damage.
There are several limitations to the present study. One 
is that we could not directly clarify that hANP prevents an 
increase in postoperative serum Cr, although it did reduce the 
incidence of AKI, as determined by serum Cr levels based 
on the definition of AKI, probably because of the small sam-
ple size, although hANP could inhibit the secretion of uri-
nary NGAL and L-FABP. Second, this study was not blinded 
because carperitide (hANP) has been used as a protective 
agent during cardiac failure only in Japan, and the utility of 
hANP in the prevention of AKI or the safety of patients with 
its administration during surgery has not been completely 
confirmed. Hence, our institutional ethics committee was 
not in favor of blinding in the study, although several stud-
ies have reported the protective effects of hANP on renal 
damage [7, 8, 23]. Third, we could not directly prove that 
hANP prevents activation of the intrarenal RAAS through 
the secretion of urinary angiotensinogen, which is an indica-
tor of intrarenal RAAS activity. Moreover, hANP inhibited 
the activity of the systemic RAAS to some extent, although 
the level of inhibition was not significant. Hence, there is still 
the possibility that inhibition of the activity of the systemic 
RAAS by hANP reduced the incidence of postoperative 
AKI. Further research, including in vivo and in vitro experi-
ments, is needed to clarify the role of hANP in the intrarenal 
RAAS. In addition, we had intended to decide sample size 
based on the previous studies. However, the previous studies 
adopted the values of serum Cr concentrations as the index 
of AKI after cardiac surgery, while we defined the incidence 
of AKI based on KDIGO criteria, which adopted the increas-
ing degrees of serum Cr, and there are few reports showing 
the efficacy of hANP in this manner. Therefore, we could 
not apply the previous power calculation to the present study 
for the determination of sample size. Also, we excluded aor-
tic graft surgery from the study based on the advice of our 
expert statistician, because blood loss, CPB time and opera-
tive time were much larger than in other cardiac surgeries. A 
larger trial including aortic graft surgery with power calcula-
tion based on the present results is anticipated.
In conclusion, the efficacy of hANP for prevention of peri-
operative renal damage was investigated in the present study. 
hANP exerted renoprotective effects during cardiac surgery, 
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and can possibly reduce the incidence of AKI after ischemia–
reperfusion surgery. Moreover, this protective effect of hANP 
is mainly induced by inhibition of the intrarenal RAAS.
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